Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurizio Scaltriti

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
The Journal of Pathology|October 10, 2013
Biomarkers of drugs targeting HER-family signalling in cancerFilippo Montemurro, Maurizio Scaltriti
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
The epidermal growth factor receptor pathway: a model for targeted therapyMaurizio Scaltriti, José Baselga
Nature Reviews. Clinical Oncology|October 19, 2018
NTRK fusion-positive cancers and TRK inhibitor therapyEmiliano Cocco, Maurizio Scaltriti, Alexander Drilon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2016
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to TherapyMaurizio Scaltriti, Moshe Elkabets, José Baselga
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2012
Molecular pathways: targeting hsp90--who benefits and who does notMaurizio Scaltriti, Shaheenah Dawood, Javier Cortes
Current Pharmaceutical Design|September 15, 2012
PI3K pathway inhibitors: better not left aloneBen Markman, Jessica J Tao, Maurizio Scaltriti
Cancer Research|September 3, 2004
Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1Maurizio Scaltriti, Anna Santamaria, Rosanna Paciucci, et al.
Cancer Convergence|April 7, 2018
A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancerJorge Gómez Tejeda Zañudo, Maurizio Scaltriti, Réka Albert
Breast Cancer Research : BCR|May 24, 2011
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanismGloria Fuentes, Maurizio Scaltriti, José Baselga, et al.
Breast Cancer Research : BCR|April 19, 2015
Quantification of HER family receptors in breast cancerPaolo Nuciforo, Nina Radosevic-Robin, Tony Ng, et al.
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
The Journal of Pathology|October 10, 2013
Biomarkers of drugs targeting HER-family signalling in cancerFilippo Montemurro, Maurizio Scaltriti
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
The epidermal growth factor receptor pathway: a model for targeted therapyMaurizio Scaltriti, José Baselga
Nature Reviews. Clinical Oncology|October 19, 2018
NTRK fusion-positive cancers and TRK inhibitor therapyEmiliano Cocco, Maurizio Scaltriti, Alexander Drilon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2016
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to TherapyMaurizio Scaltriti, Moshe Elkabets, José Baselga
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2012
Molecular pathways: targeting hsp90--who benefits and who does notMaurizio Scaltriti, Shaheenah Dawood, Javier Cortes
Current Pharmaceutical Design|September 15, 2012
PI3K pathway inhibitors: better not left aloneBen Markman, Jessica J Tao, Maurizio Scaltriti
Cancer Research|September 3, 2004
Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1Maurizio Scaltriti, Anna Santamaria, Rosanna Paciucci, et al.
Cancer Convergence|April 7, 2018
A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancerJorge Gómez Tejeda Zañudo, Maurizio Scaltriti, Réka Albert
Breast Cancer Research : BCR|May 24, 2011
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanismGloria Fuentes, Maurizio Scaltriti, José Baselga, et al.
Breast Cancer Research : BCR|April 19, 2015
Quantification of HER family receptors in breast cancerPaolo Nuciforo, Nina Radosevic-Robin, Tony Ng, et al.
Pageof 14